Head-to-head evidence
AZD0780 vs Lerodalcibep
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Atherosclerotic Cardiovascular Disease
Shared mechanism: PCSK9 · full Atherosclerotic Cardiovascular Disease pipeline
AZD0780
Developed by AstraZeneca
NCT06173570 · Phase 2 · completed
The study randomized 428 participants to four AZD0780 dose groups or matched placebo and used quadruple blinding of participants, care providers, investigators, and outcome assessors. Its primary endpoint was the regulator-accepted lipid measure LDL cholesterol, and all four AZD0780-versus-placebo comparisons were statistically significant in the favorable direction (p<0.001).
Next expected readout: January 2027 · NCT07000136 (registry estimate)
Lerodalcibep · Lerochol
Marketed by LIB Therapeutics
NCT04797104 · Phase 3 · completed
This was a randomized, quadruple-blind, placebo-controlled trial in 478 patients that measured LDL-cholesterol lowering, the standard efficacy measure for this drug class. Lerodalcibep reduced LDL-C by more than half compared with placebo, a highly statistically significant result.
Next expected readout: July 2028 · NCT07102511 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: AZD0780's landscape · Lerodalcibep's landscape